Last reviewed · How we verify
NCT05904704
Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors
NA trial testing Magnetic Resonance Imaging in Intracranial Neoplasm. Withdrawn.
31 March 2029
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 12 April 2023 |
| Primary completion | 31 March 2029 |
| Estimated completion | 31 March 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Magnetic Resonance Imaging
- Oxygen Therapy — full drug profile →
Conditions studied
- Intracranial Neoplasm — all drugs for Intracranial Neoplasm →
Sponsor
OHSU Knight Cancer Institute
Who can join
18 and older, any sex, with Intracranial Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial evaluates the feasibility of performing oxygen-enhanced magnetic resonance imaging (MRI) to generate hypoxia maps in patients with intracranial tumors. Decreased levels of oxygen (hypoxia) is a hallmark of malignant brain tumors. Chronic hypoxia is a stimulator of blood vessel formation, which is required for tumor growth and spread. Hypoxia also limits the effectiveness of radiation and chemotherapy. MRI is an imaging technique that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The administration of inhaled oxygen allows for an increased MRI signal effect size. Oxygen-enhanced MRI may be a non-invasive method that can physiologically estimate tissue hypoxia. With a better understanding of the extent of tumor hypoxia, more effective and patient-specific therapies could be devised to halt malignant tumor growth.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pancreatic Ductal Adenocarcinoma: The Characteristics of Contrast-Enhanced Ultrasound Are Correlated with the Hypoxic Microenvironment.
Wang L, Li M, Dong T, Li Y, et al · · 2023 · cited 4× · PMID 37892091 · DOI 10.3390/diagnostics13203270
Verify or expand the search:
- PubMed search for NCT05904704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Magnetic Resonance Imaging
Trials testing the same drug.
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
Other recruiting trials for Intracranial Neoplasm
Currently open trials in the same condition.
- NCT06474533 — Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm · recruiting
- NCT05891002 — Accuracy of Robotically Assisted Cranial Biopsies · recruiting
- NCT04278118 — Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study · NA · recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05904704 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 14 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing